158 Addendum LIST OF PUBLICATIONS Bos MK*, Verhoeff SR*, Oosting SF, Menke-van der Houven van Oordt WC, Boers RG, Boers JB, Gribnau J, Martens JWM, Sleijfer S, van Herpen CML, Wilting SM; Methylated cell-free DNA sequencing to identify early progression in metastatic renal cell carcinoma patients on watchful waiting Cancers. 2023 Feb; 15(5):1374 Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L, Heskamp S, Desar IME, Menke-van der Houven van Oordt WC, van der Veldt AAM, Arens AIJ, Brouwers AH, EssenEisses B, Mulders PFA, Hoekstra OS, Zwezerijnen GJC, van der Graaf WTA, Aarntzen EHJG, Oyen WJG, van Herpen CML; The value of [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict watchful waiting duration in patients with metastatic clear cell renal cell carcinoma Clinical Cancer Research. 2023 Feb; 29(3):592-601. Verhoeff SR, van de Donk PP, Aarntzen EHJG, , Oosting SF, Brouwers AH, Miedema IHC, Voortman J, Menke-van der Houven van Oordt WC, Boellaard R, Vriens D, Slingerland M, Hermsen R, van Engen-van Grunsven I, Heskamp S, van Herpen CML; [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in patients with recurrent or metastatic head and neck cancer Journal of Nuclear Medicine. 2022 Oct; 63(10):1523-1530 Westdorp H, Verhoeff SR, Gotthardt M, Heskamp S, Aarntzen EHJG; Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies Journal of Nuclear Medicine. 2022 Nov; 63(11) Verhoeff SR, van den Heuvel MM, van Herpen CML, Piet B, Aarntzen EHJG, Heskamp S. Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy? Pet Clinics. 2020 Jan; 15(1):35-43 Verhoeff SR*, van Es SC*, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EHJG, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML. The value of [89Zr] Zr-girentuximab and [18F]FDG PET scan in detecting metastatic clear cell renal cell carcinoma Eur J Nucl Med Mol Imaging. 2019 Aug; 46(9):1931-1939 Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer Int J Cancer. 2016 Jul; 139(1):187-193
RkJQdWJsaXNoZXIy MTk4NDMw